Literature DB >> 6183969

Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction.

C W Pumphrey, J Dawes.   

Abstract

The plasma concentration of beta-thromboglobulin (BTG), a platelet-specific protein released during platelet aggregation, is considered a sensitive marker of in vivo platelet activity. The mean plasma level in 133 asymptomatic individuals was 32.3 +/- 1.1 ng/ml, and there was no difference between those with no risk factors (32.2 +/- 1.2 ng/ml, n = 56), those who smoked (31.8 +/- 1.8 ng/ml, n = 45), those with hyperlipidemia (32.8 +/- 1.7 ng/ml, n = 15), and those exposed to both of these risk factors (34.1 +/- 2.7 ng/ml, n = 17). The mean plasma BTG level in 104 patients with symptomatic ischemic heart disease was significantly elevated (40.9 +/- 1.4 ng/ml, p less than 0.01), but there was considerable overlap with normal levels. Although no difference was found between patients with no risk factors (38.1 +/- 4.0 ng/ml, n = 13) and those with only 1 risk factor (37.0 +/- 1.8 ng/ml, n = 44), patients with 2 or more risk factors ahd a significantly elevated plasma BTG level (45.2 +/- 2.2 ng/nl, n = 47, p less than 0.01). It is concluded that risk factors themselves do not increase platelet activity, but that patients with vascular disease have activated platelets that may contribute to the progression of the disease. Plasma BTG was also measured serially for 10 days in 29 patients after hospitalization with acute ischemic cardiac pain. Although the median plasma level was elevated above normal there were no acute changes in plasma BTG after either acute infarction (n = 22) or acute ischemia (n = 7), except in 2 patients in whom pericardial friction rubs developed. Thus, measurement of systemic plasma BTG did not detect platelet involvement in acute coronary occlusion or acute ischemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183969     DOI: 10.1016/0002-9149(82)90459-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Raised concentrations of glucose and adrenaline and increased in vivo platelet activation after myocardial infarction.

Authors:  G A Oswald; C C Smith; A P Delamothe; D J Betteridge; J S Yudkin
Journal:  Br Heart J       Date:  1988-06

2.  Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department.

Authors:  V L Serebruany; D J Levine; G V Nair; A F Meister; P A Gurbel
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

3.  Platelets and coronary disease, round three.

Authors:  J R Hampton
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-09

4.  Survival in Acute Myocardial Infarction Induced by Coronary Ligation: Prognostic Relevance of Certain Hemostatic Factors During the Occlusion Phase.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

5.  The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.

Authors:  J De Cree; J Leempoels; B Demoen; V Roels; H Verhaegen
Journal:  Agents Actions       Date:  1985-07

6.  Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study.

Authors:  Louis T van Zyl; Francois Lespérance; Nancy Frasure-Smith; Alex I Malinin; Dan Atar; Marc-André Laliberté; Victor L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2008-01-11       Impact factor: 2.300

7.  Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies.

Authors:  Yue Liu; Hui-Jun Yin; Da-Zhuo Shi; Ke-Ji Chen
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-21       Impact factor: 2.629

8.  Study on the platelet factor and beta-thromboglobulin in the patients with ischemic heart disease.

Authors:  M H Kim; S H Huo; K S Kim; M S Kim; J S Song
Journal:  Korean J Intern Med       Date:  1986-01       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.